Prelude Therapeutics Inc at Evercore ISI HealthCONx Virtual Conference Transcript

Dec 01, 2021 / 02:15PM GMT
Josh Schimmer - Evercore Inc. - Analyst

Welcome, everyone. It is Josh Schimmer from the Evercore ISI biotech team. Pleased to introduce Prelude Therapeutics.

Questions and Answers:

Josh Schimmer - Evercore Inc. - Analyst

Kris, give us a quick snapshot of Prelude and what you have going on there.

Kris Vaddi - Prelude Therapeutics Incorporated - CEO

Great. Sure, Josh, thanks. Thank you very much for the opportunity to participate in the fireside. Joining with me today is our Chief Scientific Officer, Peggy Scherle; and our Chief Financial Officer, Laurent Chardonnet. So we are excited to participate in this meeting. And for those of you in the audience that are new to Prelude's story, we are a clinical stage precision oncology company with a pipeline of novel compounds targeting validated pathways in cancer, all internally discovered.

We were founded in 2016 with a vision of building a precision oncology company from scratch -- a fully integrated company. And since our inception, we've been focused on
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot